 BioVie Inc. shares BIVI, 22.42 rose 19 in premarket trade Wednesday, after the biotech announced positive results from a Phase 2 trial of its Alzheimers Disease treatment NE3107. Moving away from the past focus in Alzheimers drug development on Amyloid Beta and phospho-tau, the lesions found in the brains of patients, the treatment targets neuroinflammation and insulin resistance, the company said in a statement. 